Claims
- 1. In a process for the treatment of patients having osteoporosis comprising orally administering to said patients about 50 mg sodium fluoride per day the improvement consisting essentially of the step of administering 25 mg. of sodium fluoride twice a day, to maintain a serum fluoride concentration at a therapeutic level above 95 ng/ml and less than about 190 ng/ml; each 25 mg. sodium fluoride dose being in a slow-release sodium fluoride carnauba wax formulation adopted to gradually release sodium fluoride in the small intestine.
- 2. The process of claim 1, wherein the osteoporosis is defined as being that of a post-menopausal woman.
- 3. The process of claim 1, wherein the osteoporosis is defined as being that of an elderly man.
- 4. The process of claim 1, wherein the osteoporosis may have resulted from causes, such as steroid excess or be idiopathic.
- 5. The process for claim 1, wherein the osteoporosis is defined as involving osteopenia (bone loss) but no facture.
Parent Case Info
This application is a continuation-in-part of co-pending application Ser. No. 522,014, filed on Aug. 11, 1983, now abandoned, and expressly incorporated by reference herein.
Government Interests
Developmental work relating to part of the present invention was supported by grants from the U.S. government National Institutes of Health (POI-AM 20543 and R01-AM 16061).
US Referenced Citations (8)
Non-Patent Literature Citations (2)
Entry |
Ekstrand et al., Europ. J. Clin. Pharmacol. 12:311-317, (1977), "Pharmacokinetics of Fluoride in Man After Single and Multiple Oral Doses". |
Hasvold and Ekren, Eur. J. Clin. Pharmacol., vol. 19, pp. 225-230, (1981). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
522014 |
Aug 1983 |
|